




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : G06F 19/00		A2	(11) International Publication Number: WO 99/63473
			(43) International Publication Date: 9 December 1999 (09.12.99)
(21) International Application Number: PCT/US99/12406		(81) Designated States: DE, GB, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 3 June 1999 (03.06.99)			
(30) Priority Data: 09/092,441 5 June 1998 (05.06.98) US		Published Without international search report and to be republished upon receipt of that report.	
(71) Applicant: PHASE FORWARD INC. [US/US]; 51 Winchester Street, Newton, MA 02461 (US).			
(72) Inventors: BLEICHER, Paul, A.; 174 Mt. Vernon Street, Newton, MA 02165 (US). STAMOS, Nicholas; 22 Jeannette Avenue, Belmont, MA 02478 (US). KLOFFT, Jeffrey, P.; 33 Hamilton Circle, Marlborough, MA 01752 (US). DALE, Richard, M.; 117 Russell Street, Newton, MA 02165 (US).			
(74) Agents: SMITH, James, M. et al.; Hamilton, Brook, Smith & Reynolds, P.C., Two Militia Drive, Lexington, MA 02421 (US).			

(54) Title: CLINICAL TRIAL DATA MANAGEMENT SYSTEM AND METHOD

(57) Abstract

A system and method for managing clinical trial data includes dynamically generating, at a server, a data entry form to be displayed at a client. The data entry form is generated dynamically in a SGML-derived language. Control elements within the form comprise images which are used to construct the control elements and larger controls. The form is generated from a protocol database and a context received from the client, is populated from the data database, and is published to the client. Templates based on the protocol database comprise several frames including intermediate frames for displaying frame borders which are non-horizontal and non-vertical. If the trial protocol changes during a trial, the generated form is based on the protocol version active at the time data was entered into the form. Inadvertent use of the application is discouraged requiring an authentication procedure and displaying a picture of the authenticated user. Furthermore, help is provided by creating a link between the text of each question and information about the question. The source of help may be any or all of a protocol document, an investigative brochure, and a study guide. In addition, a user, upon logging in, is presented with a dashboard screen which provides information or links to information such as trial-related news, alerts, statistical information, progress reports and a list of work to be completed.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

CLINICAL TRIAL DATA MANAGEMENT SYSTEM AND METHOD

COPYRIGHT NOTICE

A portion of the disclosure of this patent document contains material which is subject to copyright protection. The copyright owner has no objection to the facsimile reproduction by anyone of the patent document or the patent disclosure, as it appears in the Patent and Trademark Office patent file or records, but otherwise reserves all copyright rights whatsoever.

10 BACKGROUND OF THE INVENTION

Once a pharmaceutical, medical device manufacture or bio-technology company has developed a treatment, device or drug therapy, approval from a regulatory authority, such as the FDA in the US, must be obtained before it can be made available through prescription. The submission to the regulatory authority consists of a large volume of information, including clinical information which focuses on the safety and efficacy of the therapy. Much of that information is collected by conducting clinical trials.

A pharmaceutical, medical device manufacture or bio-technology company sponsors a series of clinical trials. Either an internal clinical group manages these trials or they are out-sourced to a clinical research organization (CRO). The clinical group or CRO contracts

with investigation sites that in turn recruit patients for the study and collect the clinical data.

The clinical trials are performed in a series of phases, known as Phase I, Phase II, Phase III, and Phase IV. Each phase varies in duration, the number of patients involved and purpose. Failure at any stage of Phases I, II or III of the clinical trial process effectively ends the therapy's chances for final approval.

Before entering Phase I, the sponsor needs to obtain regulatory approval. Phase I trials typically last six months and involve tens of volunteer subjects usually all of whom are located at a single investigative site. Phase I trials test the safety of the therapy. Once Phase I trials are complete and the therapy has been shown to be safe, the sponsor requests permission from the regulatory authority to proceed with further clinical tests.

Phase II trials typically last six to twelve months, involve tens to hundreds of patients and are conducted to test the effectiveness of the treatment, device or drug. A sponsor may conduct many Phase II trials, attempting to find as many uses of the therapy as possible. If the therapy appears to be effective, the sponsor requests permission from the regulatory authority to proceed with large scale trials.

For each likely use of the therapy, the sponsor conducts at least two Phase III trials. Phase III trials typically last 24 to 36 months and involve thousands of patients. Phase III trials are blinded trials, that is, a portion of the patients receive the therapy and the remaining patients receive a placebo or

active control, and the identities of patients taking the trial therapy are not known to anyone until the trial is complete. Phase III trials are conducted to test the safety and effectiveness of a therapy in a large population. The Phase III trial is the first opportunity to observe infrequent adverse effects in the general population; each and every one is carefully recorded. Since the effectiveness of the therapy is tested in a blinded environment, the results are not known until after the study is complete.

Phase IV trials occur after approval and are generally held to obtain approval to change a characteristic such as the delivery system, e.g., from liquid to tablets, or to change the status, e.g., from a prescription drug to an over-the-counter drug. Failure at any stage of a Phase IV trial effectively ends the therapy's chances of obtaining approval for such a change.

Every clinical trial has a protocol which specifies the exact timing and nature of the measurements and interventions to be performed on each patient. The protocol's time-line lists a series of events, or visits, where the data are collected from the study patient. The time-line of a typical study starts with the screening and enrollment of a patient and typically ends with the last patient visit.

Fig. 1 illustrates the preparation and processing of paperwork in a typical clinical trial. There are a number of points in the process where the data are audited and reviewed. A patient 401 visits the investigative site 413. For each visit, the protocol instructs the investigator to collect certain

information 403 about the patient 401. After the information 403 is collected, it is recorded on a Case Record Form (CRF) 405. Periodically, a Clinical Research Associate (CRA) 417 visits the investigative site 413 and compares the data in the original medical record 403 with the information on the CRF 405. This process 406 is known as source document validation, or SDV.

Once the CRF has been source document verified, CRF 405 is delivered to the organization 407 running the trial (either a CRO or an internal clinical group at the sponsor) as indicated by arrow 408. When the CRF 405 arrives at the sponsor/CRO 407, its data is entered into a clinical database 409 twice to ensure that no errors are introduced, as indicated by arrows 410A and 410B.

A medical monitor 415 and clinical data manager (CDM) 419 at the sponsor/CRO 407 examine the CRF 405 to look for inconsistencies. If any of the data are incomplete or appear incorrect, the CRF is sent back to the investigative site 413 with a query 411 for correction, a process known as cleaning. If someone at the investigative site 413 makes a change as a result of a query 411, the data is again source document verified by the CRA 417, and is sent back to the sponsor/CRO 407 for data entry, as identified by arrow 412. When all of the data cleaning is complete, the clinical database 409 is locked and data analysis begins.

As can be seen, a large volume of data is collected during each clinical trial, and the collection and management of clinical data is a large problem that requires many people performing a number of different and unique roles. These roles fall into three groups:

the investigative site roles, the clinical data review roles, and other central sponsor roles.

SUMMARY OF THE INVENTION

Implementing such a system or method on the Web has
5 the obvious advantage of ease - many people are now
familiar with Web technology and even those with
computerphobia are becoming comfortable accessing the
Web. In addition, because browsers are so inexpensive,
while the personal computers on which they run can
10 typically be had for under \$1,000, there are no major
expenses involved for other than the development of the
clinical trial database. No special software needs to
be distributed.

On the other hand, one disadvantage is that access
15 over the Web can be considerably slower than a direct
connection to a host server. Another is that certain
things that can be done easily in a closed environment
with custom software, such as curved boundaries between
frames, are not so readily done on the Web. The present
20 invention is aimed at overcoming these and other
disadvantages.

Therefore, a method of implementing a graphical
user interface (GUI) control element within a client
browser, comprising creating several bitmaps which can
25 be constructed to present the GUI control element in a
variety of different states. A Standard Generalized
Markup Language (SGML)-derived language such as HTML or
XML is used to specify placement of the bitmaps within a
document. Upon receipt of the document, a browser
30 displays a desired GUI control.

Preferably, placement of the bitmaps is specified by placing indicators such as URLs corresponding to the bit maps in certain locations, preferably table entries, within the document, such that the browser will
5 correctly display the control element. Preferably, these bit maps are used by many similar GUI controls.

Furthermore, a bitmap may be partitioned into multiple sections, where each section is associated with a different indicator.

10 In particular, in a preferred embodiment, one type of control element is a button control which comprises left, right, top and bottom pieces. A label is placed between the top and bottom pieces.

Another type of control element is a file tab, or
15 tab, control, comprising left, right, top and bottom pieces. A label is placed between the top and bottom pieces. Multiple tab controls can be grouped together, sharing bitmaps which have a left or right overlapping piece. Different bitmaps also provide different styles
20 such as color to portray a selected or non-selected tab.

Yet another type of control is a linear control which comprises button control elements spaced at intervals along a line. Each button control element has a corresponding bit map or combination of bit maps. A
25 pointer indicating a current value along the line also has an associated bitmap.

In the preferred embodiment, the server is stateless with respect to the GUI controls. That is, when a request is received, the server has no knowledge
30 of the states of the controls other than what is sent in the request.

The present invention also provides a method of entering clinical trial data from a client, where the data is maintained on a server. A data entry form to be displayed at the client, is generated at the server
5 dynamically in a SGML-derived language, from a library of code fragments. The form is generated according to the user, the patient, the protocol version within a clinical trial and data previously entered.

In a preferred embodiment, a protocol, or clinical,
10 database is created which is specific to an application. A data database is created which is specific to a subject processed by the application. Then the form is generated based on the protocol database, preferably based on a clinical protocol, and a context received
15 from the client. Preferably this is done by generating a template based on the protocol database and a context received from the client. The form or template is populated with application data from the data database, and published to the requesting client browser.

20 Preferably, the template comprises several frames including control frames with one or more control elements. An intermediate frame presents a visual attribute shared by the control frames. The appearance of the intermediate frame depends on the visual
25 appearance of the control frames.

In addition, in a preferred embodiment, protocols can be changed during the trial. The generation of the template is then further based on the protocol version which was active at time of entering data to be
30 displayed. Thus the form to be displayed is itself based on the protocol version which was active at time data was entered.

Furthermore, in a preferred embodiment, rules are associated with the displayed form, and are based on the protocol version which was active at the time of entering data to be displayed in the form.

5 Yet another aspect of a preferred embodiment of the present invention is the discouragement of inadvertent use of a computer application, by requiring a log-on procedure for each user, and displaying a picture of the currently logged-on user.

10 Still another aspect of a preferred embodiment of the present invention is the provision of context-sensitive help. Preferably, a displayed form has at least one question to which a user must respond to provide clinical data. Links are created between the
15 text of each question and detailed information related to the question. If the user clicks on text of the question, detailed information corresponding to the question is retrieved from the server is displayed.

Preferably, the detailed information is derived
20 from any or all of three source documents defining the clinical trial: a protocol document, an investigative brochure, and a study guide. Preferably, the user can walk through each of the documents.

Another aspect of the present invention is the
25 dashboard screen which provides information regarding the trial, customized for the user and presented to the user upon logging in to the system. Such information preferably includes but is not limited to trial-related news, alerts, statistical information, progress reports
30 and a list of work to be completed

BRIEF DESCRIPTION OF THE DRAWINGS

The foregoing and other objects, features and advantages of the invention will be apparent from the following more particular description of preferred embodiments of the invention, as illustrated in the accompanying drawings in which like reference characters refer to the same parts throughout the different views. The drawings are not necessarily to scale, emphasis instead being placed upon illustrating the principles of the invention.

10 Fig. 1 is a block diagram illustrating current trial data collection practice.

 Fig. 2 is a block diagram illustrating the present invention's implementation of a clinical trial data management system operating over the Internet and the
15 World Wide Web.

 Fig. 3 is a block diagram illustrating the general flow of operation and data in the present invention.

 Fig. 4A is a diagram illustrating a Web page comprising a typical clinical form created by the
20 present invention.

 Figs. 4B and 4C are illustrations depicting the hierarchical structure of a form such as that of Fig. 4A within the present invention.

 Fig. 4D is a schematic diagram illustrating the
25 dynamic construction of a form template and the resulting document within the present invention.

 Fig. 5 is a diagram illustrating how the form of Fig. 4A might appear for a different user.

 Fig. 6 is a diagram of a login screen.

30 Fig. 7 is a diagram illustrating the dashboard screen of the present invention.

Fig. 8 is a diagram illustrating intermediate frames as used by the present invention.

Fig. 9 is a diagram illustrating how a button control of the present invention comprises bit maps laid out in a table.

Fig. 10A-10C are diagrams illustrating how the tab control of the present invention comprises bit maps laid out in a table.

Fig. 11A-11D are diagrams illustrating a linear control of the present invention.

Fig. 12A is a flowchart illustrating the present invention's use of study protocol version control.

Figs. 12B and 12C are illustrations showing the same form under two different protocol versions.

Figs. 13A-13F are diagrams illustrating the use of context sensitive help as employed by the present invention.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a means of expediting the process by collecting and managing trial data including communications between sites over the Internet, using a World Wide Web (Web) server in combination with Web browsers which run on most personal computers. Such a system requires little to no investment. Communication between parties is near-instantaneous, and can be saved as part of the record. Checks can be performed automatically and instantaneously. This allows faster processing of the data, and faster availability of the data. A significant amount of time is cut out the trial time, allowing the sponsor to get its product to market

sooner, saving millions of dollars, and potentially aiding thousands or millions of potential recipients of the treatment much sooner than the treatment might otherwise be available.

5 The Internet is a world-wide computer network which actually comprises thousands of smaller networks connected to the Internet backbone, thus linking millions of computer users around the world. The Web is a technology which allows a user to format a document
10 according to some standard. The document is made accessible to a Web server which transmits the document to another user upon request. When the document is received by the requestor running a Web browser, the browser knows how to construct and display, or render,
15 the document.

Requests are made to a Web server using a Uniform Resource Locator (URL) which identifies the Web server and the specific document. These documents are often called Web "pages".

20 One common format for transmitting these documents is known as Hypertext Markup Language (HTML). HTML allows the creator of a document to specify the appearance and placement of a variety of things such as font size, style, headers and so, including placement of
25 data or pictures within tables.

If a Web page is to contain pictures, these pictures or images are often specified within the document by their respective source locations, where they are stored as image files using formats such as
30 "gif" or "jpeg", for example. These image files can be quite large and can consume an annoyingly large amount of time as a requesting party waits for the image files

to download. Of course, this is compounded when there are several image files to be downloaded.

One feature of most Web browsers is the ability to cache information locally. Thus image files can be
5 stored in the browser's cache, so that if the user requests the same page at a later time, the browser uses the locally cached image files rather than downloading the files again. While this saves much of the time that would otherwise be wasted re-downloading the images, it
10 does come with a cost: image files can be large and caching many of them for hundreds or thousands of Web pages can consume a significant portion of local memory or disk space.

Fig. 2 illustrates the present invention operating
15 over the Internet. The Clinical Research Organization (CRO) or the sponsor's own internal clinical group responsible for maintaining trial data maintains an application server 103 which stores data about the protocol, the forms to be used, the roles of various
20 individuals involved, etc., in a meta database 105. Actual clinical data collected during a trial is maintained in a trial database 107. Of course, while there are logically two databases, the actual data can be maintained in just one or many databases.

25 The application server 103 receives requests via a network 109, such as the Internet, from users 111 at the investigative sites 112, sponsor sites 113, and CRO sites 114, and responds to the requests, presenting a consistent and secure interface through a Web server
30 101. The Web server 101 transmits information to the requesting site as a document formatted according to an SGML-derived language, such as XML, or preferably,

hypertext markup language (HTML) document. The document can also include small scripts in a language such as Javascript for implementing certain rules at the user's site. Investigative sites 112 include, but are not
5 limited to, hospitals, clinics and independent doctors' offices.

During a clinical trial, various individuals have certain responsibilities which are accompanied by privileged access to certain documents. In the present
10 invention, these privileges are rigidly defined. Roles are defined as a collection of privileges such that assigning a particular individual to a defined role bestows upon that individual the collection of corresponding privileges.

15 For example, in the present invention, there are two primary roles at the investigator site. The Clinical Investigator and the Clinical Research Coordinator (CRC) gather the data for the trial according the protocol, and record the data on CRFs
20 which are sent to the sponsor for review and acceptance.

The Clinical Investigator (CI) is responsible for treating his patients and executing the study protocol. He has the ultimate responsibility for all activities at his site.

25 The CRC is responsible for collecting all of the information about the patients in the study who are being treated at the CRC's site, and for returning the information to the clinical group. In the US this individual is typically a nurse, while in Europe the
30 role of the CRC is typically performed directly by the Clinical Investigator.

The people fulfilling these roles at the investigation site must be able to see information about all of their patients who have been screened or accepted into the study. This information includes a patient's
5 visit history, the contents of the CRF associated with the patient, and the patient's lab results to name a few.

As clinical reviewers at the CRO or sponsor examine the answers to the CRF questions, they may have
10 questions or comments which require responses from the investigation site. These questions and comments are referred to as queries. The CI or CRC must be able to respond to a query, usually by attaching a comment to a question or CRF, by adding new or additional information
15 to a CRF, or by changing information previously entered on the CRF. This is a key component of data cleaning. Once the query is resolved, the response is returned to the individual reviewer who issued the query.

During the course of a trial, some patients may
20 experience adverse events. These events are noted by recording a text description of the event, as well as a medical code for that event. These codes are found in a number of coding dictionaries such as COSTART. If the adverse event is serious, the sponsor is notified
25 immediately.

Some patients in the trials may take other medications during the trial. These medications, whether taken regularly as for allergy medication, or occasionally such as aspirin for a headache, are 'coded'
30 and stored in the patient's record.

From time to time, the CI or CRC at the investigation site must review some of the information

about the study such as the study protocol, the study reference manual, a study newsletter, and a list of frequently asked questions. In addition, they must review information about individual questions on the CRF
5 such as getting a list of all previous responses to a question and viewing the discrepancy criteria for a question.

During a trial, a CI or CRC may need to communicate with a representative of the sponsor. For example,
10 initially the CI/CRC needs to provide information about the site to the sponsor (Form 1571, lab normals, CVs of the investigator). As the study progresses, the CRC may have a question or may notice something that would interest the sponsor. Much of this communication is
15 included in the study files.

In addition to communication with the sponsor, the investigation site may want to communicate with another site. Perhaps an investigation site wants to ask someone at another site a question. These
20 communications are not part of the study data.

In addition to written communication with the sponsor, frequently the site will call someone at the sponsor. The content of many of these conversions may need to be noted in the study data.

25 The study protocol may require a CI/CRC to sign the CRF pages either before the CRA performs the source document verification, when the patient book is complete or both. The signature task can be made easier for the investigator site by telling them which CRFs are
30 complete and need a signature, and when data on a signed CRF has changed and needs another signature.

Additionally, the investigator sites need to know which

CRFs they have examined and which ones they have not examined.

The management of drug inventory during a study is critical. A complete accounting of all study medication is required by the regulatory agencies. The investigator site needs to dispense study medication to their patients in the study and record this transaction. Additionally, when the sponsor issues study medication to the investigator site, this transaction and the receipt of the study medication by the investigation site must also be recorded.

Occasionally, the investigator site will need to break the study blind for a particular patient (for example, when a study patient becomes pregnant.) This is an important transaction and it must be noted in the study data.

There are four clinical review roles to be performed at the Clinical Research Organization (CRO) and/or sponsor. The Clinical Research Associate (CRA), Clinical Data Manager, Medical Monitor, and Clinical Project Manager review the data that is generated by the investigator sites for completeness and consistency.

The Clinical Research Associate reviews all of the data provided by the investigator sites, ensures that the sites are following the protocol and that all of the information in the medical record is completely and accurately represented in the study data. Typically, a CRA is responsible for monitoring a number of sites, and their audit role requires them to visit their sites. The CRA needs to know exactly what is happening at all of their sites so that they can effectively monitor the

site's activities. The CRA sends summary reports to the project manager and others at the sponsor.

The Clinical Data Manager (CDM) prepares and maintains the clinical study database. The CDM is
5 involved in the design of the study database, validation checks, and the design of the CRFs. The CDM also reviews the data in the database ensuring that the data is complete and consistent.

The Medical Monitor is often the designer of the
10 study protocol and may be responsible for making any of the necessary changes to or deviations from the protocol once that study has begun. The Medical Monitor also reviews the study data looking for data anomalies and irregularities with respect to patient safety. Like the
15 CRA, the Medical Monitor reviews the data in the CRFs and the communications with the sites. The Medical Monitor may respond to a query from a CRA. Finally, the Medical Monitor is immediately notified whenever a serious adverse event is recorded.

20 The Clinical Project Manager oversees the entire data collection process. They directly manage the activities of the CRAs and CDMs and at times they will examine the study data in detail. Together with the Medical Monitor, the Clinical Project Manager reviews
25 the progress of the study and reports status to the senior management at the sponsor.

To monitor a site effectively, a data reviewer periodically reviews the data in the CRFs. If a value is missing, the validity of a value is questionable, or
30 there is some other cause for concern, the data reviewer issues a query by attaching a question or comment to a question on the CRF.

Before a clinical database can be locked, members of the review team may be required to sign the patient CRF books. The signature task is simplified by indicating which CRFs are complete and need a signature, and which data on a signed CRF has changed and requires another signature. In addition, the data reviewer needs to know which CRFs have already been examined and which have not been examined.

Just as the site must on occasion communicate with the sponsor, the data reviewer must communicate with a site. These communications may or may not be included in the study data. In addition, some messages are critical and investigator site personnel must see these messages before continuing.

Data reviewers need to communicate with each other. A CRA may have a question for the medical monitor, or the medical monitor may notice something that they would like the CRA to investigate. Unlike queries, these communications are not part of the study database.

Occasionally, one or more of the data reviewers will want to lock some or all of the patient's records so that interim statistical analysis can be performed. A preferred embodiment of the present invention provides a mechanism for locking the data at a patient level.

The Clinical Research Associate (CRA), has specific additional functions, as well. The CRA can view an investigator site's data and issue queries to the sites.

Periodically, the CRA visits a site, reviews all of the data in the original medical records (the source documents) and compares this with the information in the CRFs. This is known as source document verification. The CRA monitors a CRF at the question level, meaning

that part of a CRF could be considered reviewed, but the rest will still need monitoring at a later time. In a preferred embodiment of the present invention, the CRA is automatically notified when any CRF is ready for
5 review.

The CRA often does not have access to the primary study database and must work off-line. Therefore, during verification the site cannot change the data being reviewed until after the review is complete.

10 The CRA must manage the documents that are provided by the site. These include any regulatory documents and any additional documents that are generated by the site that must be included with the study data. The CRA must notify the site when one of these documents is about to
15 expire.

From time to time, the CRA issues a report about a site. For example, these reports are issued when a site has been qualified for the study, when a site initiates a trial, after the CRA has monitored some of the data at
20 a site, and when a site finishes its last study patient.

The Clinical Data Manager (CDM) also has specific additional functions. During the course of a trial, the CDM may need to change one or more of the discrepancy checks in the system.

25 Typically, codes are entered not by the study coordinator (CRC) but rather by the CDM. If a CRC enters an adverse event or concomitant medication without coding the data, the CDM supplies the appropriate code in the database. In addition, the CDM
30 carefully reviews all coding of adverse events and concomitant medications, making any changes that are necessary for consistency.

-20-

The Medical Monitor is notified whenever a serious adverse event is recorded. This notification occurs as quickly as possible to ensure the safety of the affected patient and all other patients in the study.

- 5 The sponsor will occasionally send information to all members of the study team and/or to all of the sites.

- In addition, it is occasionally necessary for the Medical Monitor to change some part of the study
10 protocol or CRFs. If the change affects patient safety, the protocol change must be reviewed by an Institutional Review Board at each site before it can be implemented. This leads to the possibility that two or more versions of the protocol could be active at different sites
15 simultaneously.

- On rare occasions the Medical Monitor allows a site to violate the study protocol. When this occurs, there must be a documented record of the deviation with the Medical Monitor's approval. Additionally, the Medical
20 Monitor must note the justification for the deviation in the study data.

- Occasionally, the Medical Monitor will need to break the study blind for a particular patient (for example, when a study patient becomes pregnant). This
25 is an important transaction and it must be recorded in the study data.

The Clinical Project Manager will sometimes act as an individual contributor CRA or CDM.

- There are two other roles in the system which do
30 not fit into any of the other categories. They are the Pharmacist and the Database Manager. Many investigator sites will have their own pharmacy on site, or they will

work with a local pharmacy. In either case, the Pharmacist must have access to the clinical trial data application.

The Database Manager is responsible for the
5 security and reliability of the clinical study database. During the design of the trial, the Database Manager works with the CDM designing the implementation of the data model for the trial. At the end of the trial, the Database Manager is responsible for moving the data out
10 of the study database and into a statistical analysis database.

From time to time, a pharmacist must review information about the study such as the study protocol, the study reference manual, a study newsletter, and a
15 list of frequently asked questions. During the study, the pharmacist may need to communicate with the sponsor personnel. As the study progresses, the pharmacist may have a question or may notice something that would be of interest to the sponsor. Some of these communications
20 must be included in the study data.

The management of drug inventory during a study is critical. A complete accounting of all study medication is required by the regulatory agencies. The site needs to dispense study medication to their patients in the
25 study and record this transaction. In addition, when the sponsor issues study medication to the site, this transaction must also be recorded.

When the study is complete and the database is locked, the Database Manager must move the study data
30 into a statistical database. The database structures of the clinical database must support this conversion.

Fig. 3 illustrates the general flow of operation and data in the present invention. While any Standard Generalized Markup Language (SGML)-derived language such as XML can be used, the preferred embodiment of the present invention utilizes Hypertext Markup Language (HTML). Rectangular boxes and solid bold lines indicate process flow, while dotted lines indicate data flow.

First, at 201, a request is received from a user, i.e., an investigative site, a sponsor site, a CRO site or a pharmacist. The request 213 is saved for later processing by any or all of the authentication process 203, the application layout process 205, or the form creation process 207.

Upon receipt of a request from a client, the authentication process 203 is invoked. A user database 215 is maintained, and the authentication process 203 checks user information contained in the request 213 against the user database 215. Such information may contain user identification, password, session information, valid time frame, etc., or other equivalent authentication means.

In addition to authenticating the user, the authentication process 203 examines the user request 213 and checks with the user database 215 that the user is authorized to make such a request. The authentication process 203 can then establish which user rights 217 the user is to be given regarding the response to the particular request.

Once the requesting user has been authenticated, an application layout process 205 begins to construct the layout of the HTML response 221 to the client. This is a top layer describing what pieces are to be positioned

within the HTML document and where. For example, this layer determines what the various frames should look like and what controls should appear therein. To make these decisions, the application layout process 205
5 relies on the original user request 213, the user rights 217 as determined previously by the authentication process 203, and descriptors maintained in a descriptor database 219.

Once the layout has been generated, the form
10 creation process 207 uses the user request 213 and descriptor database 219 to determine what questions, controls and other information should go into the form in the HTML document 221 previously laid out by the application layout process 205.

15 Next, the HTML document 221 is populated with clinical data by a data population routine, which retrieves the data from a trial database 223. The document 221 is now complete and ready for transmission back to the client (block 211).

20 Fig. 4A illustrates a typical Web page 250 created by the present invention, as constructed from the HTML document 221 (from Fig. 3) when received and displayed by a client browser. Panels 251A-251C derive from the part of the HTML document 221 constructed by the
25 application layout process 205 (Fig. 3), and contain various controls and other general information.

For example, panel 251A contains a photograph 257
of the person whose user identifier and password were used to first gain access to the system, or login. As
30 discussed below, a preferred embodiment of the present invention displays this photograph 257 for the purpose

of discouraging inadvertent use of the system by another person.

Other controls 261 are also provided in this panel 251A which permit the user to navigate to and examine
5 various related documents and other information pages. Links 269 to recently accessed documents or data are also provided.

Panel 251B holds two additional controls: a time line control 263, and a file tab control 265. These are
10 special types of controls which were necessitated by the present invention, yet are not easily implemented in a Web application. They are discussed below. Note however, that the time line control 263 is used to select a specific week (or some other unit of time)
15 within the study, and that the file tab control 265 is used to select a particular form. Appearance of the form, of course, is dependent on the user's role, the protocol version and the week selected, as well as the actual form selected.

20 Finally, panel 251C holds controls 267 related to the form, here a Submit button and a Cancel button.

Once the panels 251A-251C are laid out by the application layout process 205, the selected form layout 253 is specified by the form creation process 207 (Fig.
25 3). In Fig. 4A, the "Demographics" form is displayed.

Figs. 4B and 4C depict the hierarchical structure of an electronic CRF 253, also referred to simply as a form, of the present invention. The form 253 comprises one or more sections 551. Two sections 551 of the
30 Demographics form 253 are visible: a Demographics section and a Smoking History section. The remainder of

the form can be brought into view by scrolling the scroll bar 553.

Each section comprises one or more items in which the user is typically asked to provide information about a patient, or if the information has already been provided, the information is displayed. For example, the Demographics section 551 has six items 554 numbered from 1 to 6, as well as a seventh item 555 in which a calculation is automatically performed by the system.

Each item 554 in turn may comprise one or more control groups 556. For example, item 2 ("Date of Birth") comprises control group 556, which in turn comprises three controls 557A-557C (generally 557 in Fig. 4C). Note that a control group may itself comprise control groups.

Each control may have one or more elements. For example, control 557A allows a user to select the patient's date of birth month. The twelve months are available in a list which is made visible by clicking on the arrow. Each month is an element 558 of the control 557A.

The significance of this hierarchy is that each of these hierarchical levels is treated as an object, with its own HTML fragments. As illustrated in Fig. 4C, when a user sends a request 201 for a specific form, the associated form object 253 is called up and passed user 559 and form 560 information. Form construction is begun by selecting certain HTML fragments. The form object 253 then determines from the trial database including information about the protocol version, and from user privileges and patient information, which

sections are to be included, and those section objects are then called by the form object to render themselves.

As with the form object, each section object has its own HTML fragments, some of which are selected.

- 5 This process continues, each object in the hierarchy selecting HTML fragments according to the user privileges, and calling its embedded objects.

Fig. 4D further illustrates how the HTML document 211 is constructed dynamically from fragment templates and from data. A trial database 220 stores structural information of the form object hierarchies as previously discussed. A descriptor database 219 is essentially a library of HTML code fragments. These two databases together make up the meta database 105. A clinical database 223 stores data collected during the trial.

For example, the Demographics Form is described as having two sections, Section 1 and Section 2. In the preferred embodiment, pointers are used, such as the pointer 230 to Section 1. Each section in turn has pointers to its items, and so on.

Each part of the hierarchy also points to corresponding code fragments in the descriptor database 219. For example, the high level Demographics form object comprises a pointer or identifier 231 which points to various code fragments 234. The object decides which fragments to use and which to reject, depending on user rights. The selected template fragment is copied (indicated by 238) into the document 211.

30 Each object in the hierarchy behaves similarly. Section 1 object data in the trial database 220 has a pointer 232 to its own corresponding code fragments in

-27-

the descriptor database 219. Again, those code fragments or templates selected, such as code fragment 235, are copied into the document 211, as indicated by arrow 239.

5 In addition, the object for Section 1 also has a pointer to data 236 stored in the clinical database 223 which is combined, in the output document 211, as indicated by arrow 240, with the fragment template 235. The data 236 is copied, as indicated by arrow 241, into
10 the document 211, and replaces some placeholder from the original fragment. The copied data is indicated by reference 242.

 Finally, the output document 211 is sent, or published, to the requestor, whose browser renders the
15 form. Arrow 243 demonstrates how one of the section fragments with trial data is rendered into a section 204 of the form.

 Of course, the clinical data is initially entered by the CI/CRC and stored in the trial database when
20 submitted. Upon later retrieval for review or editing (assuming proper user rights), the stored data is filled in under the data population process 209 (Fig. 3), wherein individual control or element objects retrieve and display actual clinical data from the clinical
25 database 223.

 Note that while code fragments are generally in the form of HTML statements, they can also contain small scripted statements written in a language such as Javascript, which might be used to implement certain
30 rules. For example, a rule might allow patient temperatures only within a certain range, to protect against the entering of Celsius temperatures instead of

Fahrenheit. Checking with rules at the browser using a language such as Javascript obviates the extra transmissions back and forth that would be required if all checks were to be done at the server. Such rules
5 may be based on the protocol which was active at the time certain data was entered.

In Fig. 4B, an inconsistency in the data has been found. The user has indicated in Question 7 that the patient has never smoked, yet in Question 9 has
10 indicated that the patient smokes cigarettes. Thus a query 271 has been entered by a CRA asking for further verification and appears on the form for the user to respond to.

Finally, note that the text of each question is a
15 link to additional information. For example, the text 271 of Question 5, "Weight" is a link to one of several documents explaining weight in the context of the protocol. This is discussed further below.

Fig. 5 illustrates how, in the preferred
20 embodiment, the same form can differ for a different user with a different role and therefore different access rights. Here, User2 is a Clinical Research Associate (CRA) with the Sponsor. The Sponsor is not allowed to enter or alter data. Thus patient data at
25 275 is simply displayed as text and is not editable. No controls are available.

Note also that for User2, different controls 277 are provided in the application layout panel 251A. Here, there are two additional controls: Signatures and
30 Monitor, because these are CRA functions. Note also that because the form does not allow data entry, the

controls in pane 251C are also different from those of Figs. 4A and 4B.

Preventing inadvertent use

Fig. 6 illustrates a typical login screen of the present invention as displayed on a client browser. A user is asked to provide an account name 293 and a password 295. Upon clicking on the Log In button 297, the account name and password are transmitted over the Internet to the Web Server 101 (Fig. 2) where they are then submitted to the Application Server 103 for authentication. Alternatively, authentication could be performed using alternative methods such as a secure identification card, digital certificates or biometric characteristics.

A preferred embodiment of the present invention displays a photograph 257 (Fig. 4A) for the purpose of discouraging inadvertent use of the system by another person. For instance, if the person logged in happens to walk away for a break, take a telephone call, etc. and another user comes along and logs in using his own login, and this second user takes a break, while the first user returns, the first user will see instantly that she is no longer logged in. A photograph catches the attention of the user much more readily than would a text-only name.

In the preferred embodiment, the name and role 259 of the logged-in user are provided under the photograph 257. Thus, if the first user forgot to log out, a second user coming upon the system, and unfamiliar with the first user, could visually identify the first user, or, if unable to find the first user, because the name

is provided, could look the first user up in a directory if it were necessary to contact the first user.

Integrated Dashboard

In a preferred embodiment, when the user has been authenticated, a "dashboard" 301 customized to the user is returned to the client browser and displayed.

Fig. 7 is a diagram illustrating the dashboard screen of the present invention. The dashboard 301 contains various information and links regarding the study. For example, it contains study news 303 which the user should read and alerts 305 which may be critical. It also contains study progress graphs 307, a list of work to be completed 309 with navigational links, and additional information. It serves as a home base for the user.

Intermediate Frames

While frames with curved corners can be aesthetically pleasing, HTML frames do not provide such curved borders. Thus one aspect of the present invention is the use of intermediate frames to provide the curves.

Fig. 8 is a diagram illustrating the use of an intermediate frame by the present invention. Normally, a Web display may be broken down into several independent frames. Here, Web page 400 is divided functionally into three independent frames: a control panel frame 403, a content action panel frame 405 and a content panel frame 407.

The developer of the Web site wishes to use a curved line 401 to visually differentiate the panels

from each other. However, in HTML, frame borders are limited to horizontal and vertical lines.

A preferred embodiment of the present invention simulates curved or irregular shapes between frames by using an intermediate frame 409 between frames 403, 405 and 407 in which the curves and other frame borders are drawn. Thus, it appears to the user that the various panels actually have curved borders.

Bit Mapped Controls

As discussed earlier, in a preferred embodiment of the present invention, typical GUI controls which are normally executed in a stateful machine are implemented in a client browser. This is done in the preferred embodiment of the present invention by creating several bitmapped images which can be selectively placed such that the browser properly constructs the desired control. Bitmapped images may be formatted as gif, jpeg or other formats. Because browsers cache images locally, reuse of most of the bitmaps in multiple control elements results in rapid construction of the control element and thus the Web page.

One advantage of this approach is that because many of the images are reused, only one copy of each needs to be downloaded from the server. Second, labels are simple text and do not have associated images to be downloaded. The text is small and thus takes only a short time to transfer. Finally, because the image files corresponding to the bitmaps are locally cached by a browser, and because the image files are small, they consume only a small portion of memory.

Fig. 9 illustrates this concept with a button control 501 containing the text label "ABC" 503. Ordinarily this entire button 501 is a single image. If many buttons are used, say having labels "DEF", "GHI" and so on, each must have a completely different image, each requiring its own initial transfer time and its own cache storage.

Instead, the present invention breaks the button image into several images 505A-505D. References or indications such as URLs to these images (which, in the preferred embodiment are generally "gif" files) are placed into a TABLE structure in an HTML document. Such a table 506 has five data entries, labeled 506A-506E. References to images 505A-505D are placed in four of the table entries 506A-506D, resulting in the placement by a browser, of the images in the table 506, as indicated by arrows 509A-509D respectively. The label text "ABC" is placed, with a background color matching the images 505A-505D, into the remaining table entry 506E.

Thus, while the application may use many different buttons, only the labels are different - the same images are reused by all of the buttons. No additional image files need to be transferred over the Internet. Only the text needs to be transferred and text takes but a fraction of the time an image takes to transfer. Since the images are reused, storage in the cache is much smaller as well.

Note also that an HTML-compatible browser automatically extends bitmapped images to fit a required space. Since a table adjusts itself to contain its data entries, a button 501A having a long label 503A (say the entire alphabet) would be drawn having a label space

-33-

506E long enough to contain the entire label. Table entries 506B and 506C would be lengthened accordingly, and therefore bitmapped images 505B and 505C would be extended to fill these lengthened entries, even though only minimal descriptions of the bitmaps is provided.

Below is sample HTML code to produce a button from several gif files. Bitmap images 505A-505D (Fig. 9) correspond to files named respectively

"but_bot_left.gif", "but_bot_top.gif",
 10 "but_bot_right.gif", and "but_bot_bot.gif". The label of this particular button is "Go". Note also that each of the table entries has the text: HREF="tabs.htm". Thus clicking anywhere on the button will cause the browser to request a Web page identified as "tabs.htm".

```
15 <HTML>
  <!--////////////////////////////////////
  -->
  <!--//      Copyright (c) 1997-1998 Phase Forward Inc.
  -->
  20 <!--//      51 Winchester Street, Newton MA 02161
  -->
  <!--//      All Rights Reserved
  -->
  <!--////////////////////////////////////
  25 -->
```

```

  <HEAD>
  <STYLE>
  TD
  {
  30     font-size: 8pt;
        font-family: Arial,"Sans Serif";
        text-align: center;
        vertical-align: middle;
        font-weight: bold;
  35     color:#CCCCCC;
  }
  TD.menu
  {
  40     line-height: 10px;
        height: 8px;
```

-34-

```

    }
    TD.TDLeft
    {
        text-align: left;
5        vertical-align: middle;
    }
    TD.TDRight
    {
        text-align: right;
10        vertical-align: middle;
    }
    A:link
    {
        color: #CCCCCC;
15        font-size: 8pt;
        font-family: Arial,"Sans Serif";
        font-weight: bold;
        text-align: center;
        text-decoration: none;
20    }
</STYLE>
</HEAD>
<BODY>
    <TD NOWRAP TITLE="Click here to go to the patient
25 visit">
        <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0"
            VALIGN="middle" ALIGN="left">
            <TR>
                <TD ROWSPAN="3" NOWRAP><A HREF="tabs.htm"><IMG
30 SRC="./images/but_bot_left.gif"
                BORDER="0"></A></TD>
                <TD NOWRAP><A HREF="tabs.htm"><IMG
                SRC="./images/but_bot_top.gif" WIDTH="34"
                HEIGHT="4" BORDER="0"></A></TD>
35 <TD ROWSPAN="3" NOWRAP><A HREF="tabs.htm"><IMG
                SRC="./images/but_bot_right.gif"
                BORDER="0"></A></TD>
            </TR>
            <TR>
                <TD CLASS="menu" BGCOLOR="#336699" NOWRAP><A
40 HREF="tabs.htm">Go</A></TD>
            </TR>
            <TR>
                <TD NOWRAP><A HREF="tabs.htm"><IMG
45 SRC="./images/but_bot_bot.gif" WIDTH="34"
                HEIGHT="5" BORDER="0"></A></TD>
            </TR>
        </TABLE>

```

```
</TD>  
</BODY>
```

Note that in HTML, a table structure is delimited by the <TABLE> and </TABLE> tags. Each row begins with the tag <TR> and optionally ends with </TR>. Within each row, each column, or table data, begins with <TD> and optionally ends with </TD>. A COLSPAN=X or ROWSPAN=Y specification within a <TD> tag indicates that the corresponding entry is to span X columns or Y rows respectively.

Figs. 10A, 10B and 10C illustrate a file tab, or tab, control used by the present invention. Fig. 10A shows a tab control 421 having three tabs, although a tab control with any number of tabs can be implemented with this technique. As shown, the first tab element, labeled "ABC" is selected.

The tab control 421 is subdivided into many small sections, shown individually in Fig. 10C, each of which, except for label sections, has a corresponding image. As with the button control, many of the images are reused. Each image has a shaded version and an unshaded version. A tab is shaded if it has been selected. For example, a right piece bitmap 437, a top piece bitmap 425, and a bottom piece bitmap 429 define most of the third "GHI" tab. The label 435 is not a bitmap but rather, as with button labels described above, is simply text with a background color to match the surrounding bitmaps. Bitmap 431 is shared by the "GHIC" tab and the adjacent "DEF" tab.

The "DEF" tab uses the same top and bottom piece bitmaps 425, 429. Therefore, these bitmaps will not have to be transferred again since they were just

transferred in order to draw them into the "GHI" tab. Of course, the "DEF" tab here uses a unique label ("DEF"), but since that is simple text, it is placed directly in the table structure and as a result there is
5 no significant overhead in its transmittal. Another overlapping piece bitmap 431A is shared between the "DEF" tab and the selected "ABC" tab.

The "ABC" tab uses shaded left, top and bottom piece bitmaps 423A, 425A, 429A respectively, to show
10 that the "ABC" tab is selected. The label "ABC" 427 is data embedded directly in the table data definition.

Each of these small bitmap images has a HREF element assigned to it, i.e. a reference to send to the server if the user clicks the mouse button on the
15 bitmap. Although the same top bitmap 425 is used for multiple tabs, each realization of the bitmap may have a different HREF assignment. Thus, for example, when the user clicks anywhere within any of the top 425 or bottom 429 bitmaps or the label 427 associated with the "DEF"
20 tab, information regarding "DEF" may be retrieved from the server and displayed on the browser. In addition, the tab control appearance must change to indicate that "DEF" has been selected.

Thus, the tab control now appears as shown in Fig.
25 10B. Only two new images are required: the shared bitmap 431A between the "ABC" and "DEF" tabs has been replaced by a bitmap 439A with a different overlapping appearance, and the leftmost piece 423A is no longer shaded and must be replaced with piece 423. These are
30 the only piece of the tab control that need to be provided by the server.

As with the button discussed above, without this technique, it is necessary to download and cache the entire tab control in each of its three possible states, i.e. three bitmap of the entire tab control, each with a different tab selected. This requires much more cache memory than the present invention, as well as much more transmission time when the maps have not been cached (and each transmission is a transmission of the entire tab control bitmap.) The present invention, on the other hand, uses one small top bitmap 425 for each tab, as well as a bottom 429, left 423, and right 437 pieces, or their shaded versions 425A, 429A, 423A, 437A respectively, and right overlap 431A and left overlap 439A pieces all of which are significantly smaller than the whole. This difference becomes even more significant where the number of tabs is larger. As with the button control, the top and bottom tab bitmaps 425, 429 respectively can be extended and therefore the actual bitmaps are extremely small, just a few pixels wide and therefore consume a very small amount of cache memory.

Another advantage to the present invention is that if the form changes so that the tab control has additional tabs, no further bitmaps need to be transferred. All of the necessary bitmaps will have been cached. Only the table structure with text labels, tab selection information, and references to the bitmap files needs to be transferred.

Yet another advantage is that the present invention alleviates the need to create more images when a form changes. For example, in the prior art, if a tab control comprises seven individual tab control elements,

seven different images must have been created - each one having a different tab selected. If it becomes necessary to add an eighth tab control element, eight new images must be created. In the present invention,
 5 no further images need to be created.

Preferably, these bitmaps are arranged by placing them in a table structure. For example, the code below defines an HTML table in which the positions and files containing the bitmaps are specified.

10 Also, in a preferred embodiment, the selected tab (whose associated form is displayed) is colored differently and rendered differently than the non-selected tabs. Thus there are different images for selected and non-selected tab parts. However, since a
 15 label is simply text and no image is used, a label's background color is specified within the corresponding table entry to match the tab. There is no image file to be transferred.

The following sample code produces a file tab
 20 control with five tabs labeled "VS", "LAB", "AE", "CM", and "CMP" respectively, with "VS" indicated as the selected form.

```

<HTML>
<!--////////////////////////////////////
25 -->
<!--//      Copyright (c) 1997-1998 Phase Forward Inc.
-->
<!--//      51 Winchester Street, Newton MA 02161
-->
30 <!--//      All Rights Reserved
-->
<!--////////////////////////////////////
-->

<HEAD>
  
```



```
<META HTTP-EQUIV="Content-Type" content="text/html;
charset=iso-8859-1">
<TITLE>Phase Forward Demo CRF Navigation Bar</TITLE>

<STYLE>
5 BODY
  {
    margin-top: 0px;
    margin-left: 0px;
    margin-right: 0px;
10    margin-bottom: 0px;
  }
  TD
  {
    vertical-align: bottom;
15  }
  TD.tabselect
  {
    color: #FFFF00;
    font-size: 10pt;
20    font-family: Arial,"Sans Serif";
    font-weight: bold;
    text-align: center;
    vertical-align: center;
    line-height: 8pt;
25    height: 11pt;
  }
  TD.tabnotselect
  {
    color: #CCCCCC;
30    font-size: 10pt;
    font-family: Arial,"Sans Serif";
    font-weight: bold;
    text-align: center;
    vertical-align: center;
35    line-height: 8pt;
    height: 11pt;
  }
  A:link
  {
40    color: #CCCCCC;
    font-size: 10pt;
    font-family: Arial,"Sans Serif";
    font-weight: bold;
    text-decoration: none;
45    text-align: center;
  }
  A:visited
```

-40-

```

    {
        color: #CCCCCC;
        font-size: 10pt;
        font-family: Arial,"Sans Serif";
5       font-weight: bold;
        text-decoration: none;
        text-align: center;
    }
A: hover
10    {
        color: #FFFFCC;
    }
</STYLE>
</HEAD>

15 <BODY BGCOLOR="#666666">

    <MAP NAME="OffMidMap1">
        <AREA SHAPE="poly" HREF="tab_vsbp.htm"
            COORDS="0,1,4,1,10,6,15,20,15,24,0,24"
            TITLE="Vital Signs/Blood Pressure">
20    <AREA SHAPE="poly" HREF="tab_lab.htm"
            COORDS="27,1,22,1,17,6,14,10,17,20,17,24,27,24,"
            TITLE="Laboratory">
    </MAP>

25    <MAP NAME="OnMidLMap2">
        <AREA SHAPE="poly" HREF="tab_lab.htm"
            COORDS="0,1,4,1,10,6,15,20,15,24,0,24"
            TITLE="Laboratory">
    </MAP>

30    <MAP NAME="OnMidRMap3">
        <AREA SHAPE="poly" HREF="tab_cm.htm"
            COORDS="27,1,22,1,17,6,14,10,17,20,17,24,27,24,"
            TITLE="Concomitant Medications">
35    </MAP>

    <MAP NAME="OffMidMap4">
        <AREA SHAPE="poly" HREF="tab_cm.htm"
            COORDS="0,1,4,1,10,6,15,20,15,24,0,24"
40    <AREA SHAPE="poly" HREF="tab_cmp.htm"
            COORDS="27,1,22,1,17,6,14,10,17,20,17,24,27,24,"
            TITLE="Study Compliance">
    </MAP>

45
```

-41-

```

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0"
HEIGHT="100%">
  <TR>
    <TD VALIGN="bottom"><TABLE BORDER="0"
5      CELLPADDING="0" CELLSPACING="0" ALIGN="left">
      <TR>
        <TD ROWSPAN="3" NOWRAP><A
          HREF="tab_vsbp.htm"><IMG
            SRC="./images/tab_off_l.gif" BORDER="0"
10          ALT="Vital Signs/Blood Pressure"></A></TD>
        <TD NOWRAP><A HREF="tab_vsbp.htm"><IMG
          SRC="./images/tab_off_top.gif" BORDER="0"
            WIDTH="52px" HEIGHT="5" ALT="Vital
              Signs/Blood Pressure"></A></TD>
15        <TD ROWSPAN="3" NOWRAP><IMG
          SRC="./images/tab_off_mid.gif" BORDER="0"
            USEMAP="#OffMidMap1"></TD>
        <TD NOWRAP><A HREF="tab_lab.htm"><IMG
20          SRC="./images/tab_off_top.gif" BORDER="0"
            WIDTH="40px" HEIGHT="5"
            ALT="Laboratory"></A></TD>
        <TD ROWSPAN="3" NOWRAP><IMG
          SRC="./images/tab_on_midl.gif" BORDER="0"
            USEMAP="#OnMidLMap2"></TD>
25        <TD NOWRAP><IMG SRC="./images/tab_on_top.gif"
          BORDER="0" WIDTH="32px" HEIGHT="5"
          ALT="Adverse Experiences"></TD>
        <TD ROWSPAN="3" NOWRAP><IMG
          SRC="./images/tab_on_midr.gif" BORDER="0"
30          USEMAP="#OnMidRMap3"></TD>
        <TD NOWRAP><A HREF="tab_cm.htm"><IMG
          SRC="./images/tab_off_top.gif" BORDER="0"
            WIDTH="34px" HEIGHT="5" ALT="Concomitant
              Medications"></A></TD>
35        <TD ROWSPAN="3" NOWRAP><IMG
          SRC="./images/tab_off_mid.gif" BORDER="0"
            USEMAP="#OffMidMap4"></TD>
        <TD NOWRAP><A HREF="tab_cmp.htm"><IMG
          SRC="./images/tab_off_top.gif" BORDER="0"
40          WIDTH="43px" HEIGHT="5" ALT="Study
            Compliance"></A></TD>
        <TD ROWSPAN="3" NOWRAP><A
          HREF="tab_cmp.htm"><IMG
          SRC="./images/tab_off_r.gif" BORDER="0"
45          ALT="Study Compliance"></A></TD>
      </TR>
      <TR>

```

-42-

```
5      <TD CLASS="tabnotselect" BGCOLOR="#336699"
        NOWRAP><A HREF="tab_vsbp.htm" TITLE="Vital
        Signs/Blood Pressure">VS/BP</A></TD>
      <TD CLASS="tabnotselect" BGCOLOR="#336699"
        NOWRAP><A HREF="tab_lab.htm"
        TITLE="Laboratory">LAB</A></TD>
      <TD CLASS="tabselect" BGCOLOR="#003366"
        TITLE="Adverse Experiences" NOWRAP>AE</TD>

10     <TD CLASS="tabnotselect" BGCOLOR="#336699"
        NOWRAP><A HREF="tab_cm.htm"
        TITLE="Concomitant Medications">CM</A></TD>
      <TD CLASS="tabnotselect" BGCOLOR="#336699"
        NOWRAP><A HREF="tab_cmp.htm" TITLE="Study
        Compliance">CMP</A></TD>
15  </TR>
      <TR>
        <TD BGCOLOR="#336699" NOWRAP><A
          HREF="tab_vsbp.htm"><IMG
20      SRC="./images/tab_off_bot.gif" BORDER="0"
          WIDTH="52px" HEIGHT="5" ALT="Vital
          Signs/Blood Pressure"></A></TD>
        <TD BGCOLOR="#336699" NOWRAP><A
          HREF="tab_lab.htm"><IMG
25      SRC="./images/tab_off_bot.gif" BORDER="0"
          WIDTH="40px" HEIGHT="5"
          ALT="Laboratory"></A></TD>
        <TD BGCOLOR="#003366" NOWRAP><IMG
          SRC="./images/tab_on_bot.gif" BORDER="0"
30      WIDTH="32px" HEIGHT="5" ALT="Adverse
          Experiences"></TD>
        <TD BGCOLOR="#336699" NOWRAP><A
          HREF="tab_cm.htm"><IMG
          SRC="./images/tab_off_bot.gif" BORDER="0"
35      WIDTH="34px" HEIGHT="5" ALT="Concomitant
          Medications"></A></TD>
        <TD BGCOLOR="#336699" NOWRAP><A
          HREF="tab_cmp.htm"><IMG
          SRC="./images/tab_off_bot.gif" BORDER="0"
40      WIDTH="43px" HEIGHT="5" ALT="Study
          Compliance"></A></TD>
        <TD VALIGN="bottom" COLSPAN="3" NOWRAP><IMG
          SRC="./images/tab_off_bot.gif" WIDTH="1000"
          HEIGHT="5" BORDER="0"></TD>
45  </TR>
      </TABLE></TD>
    </TR>
  </TABLE>
```

</BODY>
</HTML>

The correlation between bitmaps from Fig. 10C and their corresponding file names is given in the table below:

Fig. 10C ref. number	Filename in HTML code
423A / 423	tab_on_l.gif / tab_off_l.gif
425A / 425	tab_on_top.gif / tab_off_top.gif
429A / 429	tab_on_bot.gif / tab_off_bot.gif
431A	tab_on_midr.gif
439A	tab_on_midl.gif
437A / 437	tab_on_r.gif / tab_off_r.gif

Similarly, Figs. 11A, 11B and 11C illustrate a linear control, preferably a time-line control, of the present invention using the same technique. Fig. 11C shows the various bitmaps that are placed in a table structure to compose a linear control. The dashed lines show the outline of the bitmap, while the solid lines represent what is actually seen. Of course, color and shading can be used to produce a more dramatic effect, and in fact are used in the preferred embodiment.

Bitmap 481 defines the left end of the control and shows the left end of a frame which encloses the control. Similarly bitmaps 482, 483 and 489 define top, bottom and right frame pieces respectively of the control enclosure. Note that by defining a bitmap to span multiple rows or columns within a table entry does not change the appearance of the bitmap except to extend it in the vertical or horizontal direction respectively.

Bitmaps 483, and 485-488 define the various parts of the linear control itself. Bitmaps 483 and 488 are the left and right pieces respectively of the control and in the preferred embodiment are only used once per control. Bitmap 485 is the line part of the control and is used simultaneously in several places. Bitmap 486 has a continuation of the control line, plus a vertical tick. Bitmap 487 is used to show which value has been selected.

These bitmaps 481-489 can be assembled in various combinations to create linear controls of any size, and to show any control in any particular state. For example, in Fig. 11A, bitmaps 481-489 (from Fig. 11C) have been assembled into a table 451 to create a linear control with four stops. In addition, labels have been placed in the table below each stop. These labels are merely text entries with a background color matching the control, so that there is negligible overhead in obtaining the labels.

The following HTML code produces the linear control of Fig. 11A.

```

<HTML>
<!--////////////////////////////////////
-->
25 <!--//      Copyright (c) 1997-1998 Phase Forward Inc.
-->
<!--//      51 Winchester Street, Newton MA 02161
-->
<!--//      All Rights Reserved
30 -->
<!--////////////////////////////////////
-->

<HEAD>
<META HTTP-EQUIV="Content-Type" content="text/html;
35 charset=iso-8859-1">
<TITLE>Phase Forward Demo Visit Bar</TITLE>

```

-45-

```
<STYLE>
BODY
{
    margin-left: 0px;
5    margin-top: 0px;
}
TD
{
    font-size: 8pt;
10    font-family: Arial,"Sans Serif";
    font-weight: bold;
    text-align: center;
    vertical-align: middle;
}
15 TD.tdselect
{
    color: #FFFF00;
}
A:link
20 {
    color: #CCCCCC;
    font-size: 8pt;
    font-family: Arial,"Sans Serif";
    font-weight: bold;
25    text-decoration: none;
    text-align: center;
    vertical-align: middle;
    line-height: 11px;
    height: 8px;
30 }
A:visited
{
    color: #CCCCCC;
    font-size: 8pt;
35    font-family: Arial,"Sans Serif";
    font-weight: bold;
    text-decoration: none;
    text-align: center;
    vertical-align: middle;
40    line-height: 11px;
    height: 8px;
}
A:hover
{
45    color: #FFFFCC;
}
TD.tickmark
{
```

-46-

```

        vertical-align: middle;
        /*line-height: 12px;
        height: 12px;*/
    }
5  </STYLE>
  </HEAD>
  <BODY BGCOLOR="#336699">

  <TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0"
10  HEIGHT="100%" ALIGN="left" VALIGN="top">
    <TR>
      <TD ROWSPAN="3"><IMG
        SRC="./images/tick_indent_l.gif"
        BORDER="0"></TD>
      <TD COLSPAN="2"><IMG
15  SRC="./images/tick_indent_top.gif" BORDER="0"
        WIDTH="53" HEIGHT="5"></TD>
      <TD COLSPAN="3"><IMG
        SRC="./images/tick_indent_top.gif" BORDER="0"
        WIDTH="70" HEIGHT="5"></TD>
20  <TD COLSPAN="3"><IMG
        SRC="./images/tick_indent_top.gif" BORDER="0"
        WIDTH="70" HEIGHT="5"></TD>
      <TD COLSPAN="3"><IMG
        SRC="./images/tick_indent_top.gif" BORDER="0"
        WIDTH="70" HEIGHT="5"></TD>
25  <TD COLSPAN="3"><IMG
        SRC="./images/tick_indent_top.gif" BORDER="0"
        WIDTH="70" HEIGHT="5"></TD>
      <TD COLSPAN="3"><IMG
        SRC="./images/tick_indent_top.gif" BORDER="0"
        WIDTH="70" HEIGHT="5"></TD>
30  <TD COLSPAN="3"><IMG
        SRC="./images/tick_indent_top.gif" BORDER="0"
        WIDTH="70" HEIGHT="5"></TD>
      <TD COLSPAN="3"><IMG
        SRC="./images/tick_indent_top.gif" BORDER="0"
        WIDTH="70" HEIGHT="5"></TD>
35  <TD COLSPAN="2"><IMG
        SRC="./images/tick_indent_top.gif" BORDER="0"
        WIDTH="46" HEIGHT="5"></TD>
      <TD ROWSPAN="3"><IMG
        SRC="./images/tick_indent_r.gif"
        BORDER="0"></TD>
40  </TR>
    <TR>
      <TD CLASS="tickmark"><A HREF="tl_wk-4.htm"
        TITLE=""><IMG SRC="./images/tick_left.gif"
45  BORDER="0"></A></TD>

```



```

5      <TD CLASS="tickmark"><IMG
        SRC="./images/tick_line.gif" BORDER="0"
        WIDTH="35" HEIGHT="3"></TD>
      <TD CLASS="tickmark"><IMG
        SRC="./images/tick_line.gif" BORDER="0"
        WIDTH="26" HEIGHT="3"></TD>
      <TD CLASS="tickmark"><A HREF="tl_wk-2.htm"
        TITLE=""><IMG SRC="./images/tick_middle.gif"
        BORDER="0"></A></TD>
10     <TD CLASS="tickmark"><IMG
        SRC="./images/tick_line.gif" BORDER="0"
        WIDTH="26" HEIGHT="3"></TD>
      <TD CLASS="tickmark"><IMG
        SRC="./images/tick_line.gif" BORDER="0"
        WIDTH="26" HEIGHT="3"></TD>
15     <TD CLASS="tickmark"><A HREF="tl_wk0.htm"
        TITLE=""><IMG SRC="./images/tick_middle.gif"
        BORDER="0"></A></TD>
      <TD CLASS="tickmark"><IMG
        SRC="./images/tick_line.gif" BORDER="0"
        WIDTH="26" HEIGHT="3"></TD>
20     <TD CLASS="tickmark"><IMG
        SRC="./images/tick_line.gif" BORDER="0"
        WIDTH="26" HEIGHT="3"></TD>
      <TD CLASS="tickmark"><IMG
        SRC="./images/tick_line.gif" BORDER="0"
        WIDTH="26" HEIGHT="3"></TD>
25     <TD CLASS="tickmark"><A HREF="tl_wk1.htm"
        TITLE=""><IMG SRC="./images/tick_middle.gif"
        BORDER="0"></A></TD>
      <TD CLASS="tickmark"><IMG
        SRC="./images/tick_line.gif" BORDER="0"
        WIDTH="26" HEIGHT="3"></TD>
30     <TD CLASS="tickmark"><IMG
        SRC="./images/tick_line.gif" BORDER="0"
        WIDTH="26" HEIGHT="3"></TD>
      <TD CLASS="tickmark"><IMG
        SRC="./images/tick_line.gif" BORDER="0"
        WIDTH="26" HEIGHT="3"></TD>
35     <TD CLASS="tickmark"><IMG
        SRC="./images/tick_middle_selected.gif"
        BORDER="0"></TD>
      <TD CLASS="tickmark"><IMG
        SRC="./images/tick_line.gif" BORDER="0"
        WIDTH="26" HEIGHT="3"></TD>
40     <TD CLASS="tickmark"><IMG
        SRC="./images/tick_line.gif" BORDER="0"
        WIDTH="26" HEIGHT="3"></TD>
      <TD CLASS="tickmark"><A HREF="tl_wk4.htm"
        TITLE=""><IMG SRC="./images/tick_middle.gif"
        BORDER="0"></A></TD>
45     <TD CLASS="tickmark"><IMG
        SRC="./images/tick_line.gif" BORDER="0"
        WIDTH="26" HEIGHT="3"></TD>

```

```

5      <TD CLASS="tickmark"><IMG
        SRC="./images/tick_line.gif" BORDER="0"
        WIDTH="26" HEIGHT="3"></TD>
      <TD CLASS="tickmark"><A HREF="tl_wk5.htm"
        TITLE=""><IMG SRC="./images/tick_middle.gif"
        BORDER="0"></A></TD>
      <TD CLASS="tickmark"><IMG
        SRC="./images/tick_line.gif" BORDER="0"
        WIDTH="26" HEIGHT="3"></TD>
10     <TD CLASS="tickmark"><IMG
        SRC="./images/tick_line.gif" BORDER="0"
        WIDTH="28" HEIGHT="3"></TD>
      <TD CLASS="tickmark"><A HREF="tl_wk8.htm"
        TITLE=""><IMG SRC="./images/tick_right.gif"
15     BORDER="0"></A></TD>
    </TR>
    <TR>
      <TD COLSPAN="2"><IMG
        SRC="./images/tick_indent_bot.gif" BORDER="0"
20     WIDTH="53" HEIGHT="5"></TD>
      <TD COLSPAN="3"><IMG
        SRC="./images/tick_indent_bot.gif" BORDER="0"
        WIDTH="70" HEIGHT="5"></TD>
      <TD COLSPAN="3"><IMG
25     SRC="./images/tick_indent_bot.gif" BORDER="0"
        WIDTH="70" HEIGHT="5"></TD>
      <TD COLSPAN="3"><IMG
        SRC="./images/tick_indent_bot.gif" BORDER="0"
        WIDTH="70" HEIGHT="5"></TD>
30     <TD COLSPAN="3"><IMG
        SRC="./images/tick_indent_bot.gif" BORDER="0"
        WIDTH="70" HEIGHT="5"></TD>
      <TD COLSPAN="3"><IMG
35     SRC="./images/tick_indent_bot.gif" BORDER="0"
        WIDTH="70" HEIGHT="5"></TD>
      <TD COLSPAN="3"><IMG
        SRC="./images/tick_indent_bot.gif" BORDER="0"
        WIDTH="70" HEIGHT="5"></TD>
      <TD COLSPAN="2"><IMG
40     SRC="./images/tick_indent_bot.gif" BORDER="0"
        WIDTH="46" HEIGHT="5"></TD>
    </TR>
    <TR>
      <TD COLSPAN="3" STYLE='text-align:left'
45     BGCOLOR="#336699" NOWRAP><A HREF="tl_wk-4.htm"
        TITLE="Placebo Run-In Visit 1">&nbsp;Week
        &#8211;4</A></TD>

```

```

5      <TD COLSPAN="3" BGCOLOR="#336699" NOWRAP><A
        HREF="tl_wk-2.htm" TITLE="Placebo Run-In Visit
        2">Week &#8211;2</A></TD>
      <TD COLSPAN="3" BGCOLOR="#336699" NOWRAP><A
        HREF="tl_wk0.htm" TITLE="Baseline Visit">Week
        0</A></TD>
      <TD COLSPAN="3" BGCOLOR="#336699" NOWRAP><A
        HREF="tl_wk1.htm" TITLE="Treatment Visit 1">Week
        1</A></TD>
10     <TD COLSPAN="3" CLASS="tdselect" BGCOLOR="#336699"
        TITLE="Treatment Visit 2" NOWRAP>Week 2</TD>
      <TD COLSPAN="3" BGCOLOR="#336699" NOWRAP><A
        HREF="tl_wk4.htm" TITLE="Treatment Visit 3">Week
        4</A></TD>
15     <TD COLSPAN="3" BGCOLOR="#336699" NOWRAP><A
        HREF="tl_wk5.htm" TITLE="Treatment Visit 4
        (Optional)">Week 5</A></TD>
      <TD COLSPAN="3" STYLE='text-align:right'
        BGCOLOR="#336699" NOWRAP><A HREF="tl_wk8.htm"
20     TITLE="Final Visit">Week 8</A></TD>
      </TR>
    </TABLE>
  </BODY>
</HTML>

```

25 Note in addition that certain table entries have anchors, denoted by the <A> element pair. An HREF specification within an <A> element specifies the source of a document or image file. Those parts of the control corresponding to table entries having anchors with HREF
 30 specifications will cause a message to be sent to the server when a user clicks in the entry area, requesting the specified document. The server processes that request, returning pertinent information about the selected week in the form, and at the same time,
 35 resending the table with the references to the image files reordered so that the control will appear with the user's selection selected and with a form appropriate for a particular visit. Thus the control appears to work as the user would normally expect, yet all of the

work is done at the server. In addition, none (or at most one) of the bitmaps need to be downloaded because they have already been used and should be cached at the browser. Thus the transmission from server to client
5 will not be hampered by a need to download many bitmaps.

Without the present invention, it is necessary to download from the server a very large bitmap comprising the entire control in a particular state, say with the first tab selected. For each state having a different
10 tab selected, a separate, large bitmap of the entire tab control must be sent from the server if not already cached, and when these large bitmaps are cached, each consumes a very large amount of available cache memory.

Fig. 11D illustrates a variation of the time-line control 490 in which the time-line is further subdivided with small ticks 491 which do not have their own
15 associated labels, yet each is associated with a different copy of a bitmap and a HREF. For example, the ticks 491 may represent weeks within a month. Because
20 each tick 491 has its own bitmap, the user can click on one to move the pointer 492 to a particular week.

Finally, in a further embodiment of the present invention, an individual bitmap may itself be sectioned, each section being mapped to a different indicator or
25 URL, or no URL at all. For example, the file tab HTML code above uses HTML tags <USEMAP>, <MAP> and <AREA> to specify two different URLs corresponding to the left tab and right tab within the tab_off_r bitmap. That part of the bitmap not corresponding to any tab is not mapped to
30 an URL.

Protocol-version dependent forms

For various reasons, it is common during a trial for the protocol to undergo changes. Related forms must be changed to fit the new protocol when this happens. However, data entered before the change, i.e. in the old protocol, must be presented in a form corresponding to the old protocol under which it was entered.

In addition, as stated earlier, a protocol change may need to be reviewed by an Institutional Review Board at each site before it can be implemented. This can result in there being two or more active protocols at the same time. Again, the data must be presented in the form corresponding to the protocol in which the data was entered.

Fig. 12A is a flowchart illustrating the process at the server in deciding how to deliver a form to the browser depending on the study protocol version control. At block 601, a request is received from a client. The server determines what the correct study protocol version should be for the request based on date and time by looking up the protocol version of the CRF when data was first entered in the CRF. At block 605, the server determines whether the necessary form (CRF) already exists. If so the form is loaded and populated with the correct data (block 607). Otherwise, the form is created (block 609). Finally, in block 611, the correct populated form is returned to the requesting client.

Figs. 12B and 12C illustrate a CRF as it might appear in a first protocol (ref. 620 in Fig. 12B) and as it might appear in a second protocol (ref. 622 in Fig. 12C). In Fig. 12B, the CRF 620 has three items 621, 623, 625. Perhaps at the beginning of the trial, it was

-52-

established that blood pressure would be measured twice and entered into items 623 and 625.

At some point during the trial, it is decided to change the protocol so that blood pressure is to be
5 measured three times. The CRF would then appear as in ref. 622 in Fig. 12C, having an additional item 627 corresponding to the new third measurement.

Of course, for visits occurring prior to the protocol version change, there would only be two blood
10 pressure measurements on file, and so the CRF as portrayed in Fig. 12B (ref. 620) is retrieved and displayed when a user examines those visits.

Integrated help

In prior art applications, help is often available
15 in the form of a help button, or a help link. Typically, the user clicks on the help button or link, and a general help page, often accompanied with a table of contents and/or a topic index, is retrieved from the server and displayed, replacing the original page. To
20 find help, the user must search through the table of contents or the index, sometimes through several layers. To return to the original page, the user must either go back by clicking on a "Back" button in the browser, or optionally by clicking on a "Back to Document"-type link
25 or button that is typically available on the help page. Several steps are thus required to obtain help about a specific topic and then return to the original page for which help was needed.

An innovative aspect of the present invention is
30 the use of context sensitive help in a Web document. As seen in Fig. 13A, the text of each question comprises a

link to one of several trial-related documents. For instance, the text 801 "Height" for item 4 is such a link. When the user clicks on the text 801, a separate help window 803 pops open, as in Fig. 13B, and context sensitive help 804 is transferred from the server and displayed in the help window 803. This context sensitive help 804 has information specific to the text 801 clicked on - here there are specific instructions as to how to measure height, e.g. shoes off. Thus the user does not have to look for the subject in an index or table of contents, and the original page is still available - the user can close the help window at any time and the original page has not been affected.

Preferably, help comes from one of three standard sources defining the clinical trial: a protocol document, an investigative brochure, or a study guide. Note that the help window 803 comprises additional button controls 805 which enable the user to go directly to related information in any of the three documents.

In addition, a help button 807 is always available in the main panel 251A. Clicking on this button 807 brings up a general help window 809, from which a user can browse through a table of contents 810 or an index 811 for the clinical trial documents. Again, additional buttons 805 allow the user to choose a specific document. Figs. 13E and 13F show sample help screens for the protocol document 811 and study guide 812 respectively.

EQUIVALENTS

While this invention has been particularly shown and described with references to preferred embodiments

thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims. Those
5 skilled in the art will recognize or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described specifically herein. Such equivalents are intended to be encompassed in the scope
10 of the claims.

CLAIMS

What is claimed is:

1. A method of constructing a graphical user interface (GUI) application, comprising the steps of:
 - 5 creating a protocol database which is specific to an application for which data is input and displayed through a client browser, and a data database which is specific to a subject processed by the application;
 - 10 generating a template based on the protocol database and a context received from the client;
 - populating the template with application data from the data database; and
 - 15 publishing the populated template via a content server to the client browser as an SGML-derived form for input and display of data for the application.
2. The method of Claim 1 wherein generating the template is further based on the data database.
- 20 3. The method of Claim 1 wherein the protocol database is based on a clinical protocol.
4. The method of Claim 1 wherein the template comprises a plurality of frames including control frames comprising one or more control elements, and
25 an intermediate frame presenting a visual attribute

shared by the control frames, appearance of the intermediate frame depending on visual states of the control frames.

- 5 5. The method of Claim 1, wherein generating the template further comprises:

 creating a plurality of bitmaps which selectively and in combination may be constructed to present a GUI control element in plural states; specifying the template as a Standard
10 Generalized Markup Language (SGML)-derived document;

 and placing the bitmaps within the template such that upon receipt of the document at the browser, the browser will display a desired GUI
15 control.

6. The method of Claim 1, further comprising changing a first protocol version to a second protocol version; and wherein
 generating a template is further based on a
20 protocol version which was active at time of entering data to be displayed.

7. A method of entering clinical trial data from a client, whereby the data is maintained on a server, the method comprising:
25 defining a first protocol under which the clinical trial is to be run;
 allowing the first protocol to be changed to a second protocol anytime during the trial; and

displaying a form at the client, wherein the form is based on a protocol which was active at time of entering data to be displayed in the form.

- 5 8. The method of Claim 7 wherein the form is selected from a library of forms.
9. The method of Claim 7 wherein the form is dynamically generated.
- 10 10. The method of Claim 7 wherein rules associated with the displayed form are based on the protocol version which was active at the time of entering data to be displayed in the form.
- 15 11. A clinical trial data entry method, comprising:
displaying a form on a computer screen, the form having at least one question to which a user must respond to provide clinical data;
creating links between text of each question and detailed information related to the question; and
if the user clicks on text of the question,
20 displaying detailed information corresponding to the question.
12. The method of Claim 11 wherein the detailed information displayed is a help document defining the clinical trial.

13. The method of Claim 12 wherein the help document is one of a protocol document, an investigative brochure, and a study guide.
14. The method of Claim 12 wherein the help document
5 comprises all of a protocol document, an investigative brochure, and a study guide.
15. A clinical trial data entry method, comprising:
displaying a form on a computer screen, the
form having at least one question to which a user
10 must respond to provide clinical data;
upon a user request, displaying detailed
information from any or all of a protocol document,
an investigative brochure, and a study guide.
16. The method of Claim 15 wherein the user can walk
15 through each of the protocol document, investigative brochure and study guide.
17. The method of Claim 16 wherein the detailed
information displayed is from a section of the
protocol document, investigative brochure, or study
20 guide, which section pertains immediately to the question to which the user must respond.
18. A method of constructing a graphical user interface
(GUI) clinical trial application, comprising the
steps of:
25 providing a user login procedure;
upon a user logging in, presenting to the user
a dashboard screen comprising information regarding

the trial, the dashboard screen being customized for the user.

19. The method of Claim 18 wherein the information comprises trial-related news.
- 5 20. The method of Claim 18 wherein the information comprises alerts.
21. The method of Claim 18 wherein the information comprises statistical information.
22. The method of Claim 18 wherein the information
10 comprises progress reports.
23. The method of Claim 18 wherein the information comprises a list of work to be completed.
24. A method of implementing a graphical user interface (GUI) control element within a client browser,
15 comprising the steps of:
 - creating a plurality of bitmaps which selectively and in combination may be constructed to present the GUI control element in plural states;
 - 20 specifying placement of the bitmaps within a Standard Generalized Markup Language (SGML)-derived document such that upon receipt of the document at the browser, the browser will display a desired GUI control.

25. The method of Claim 24 wherein the step of specifying placement of the bitmaps further comprises the step of placing indicators to the bit maps in certain locations within the document, such
5 that the browser will correctly display the control element.
26. The method of Claim 25 wherein the indicators are uniform resource locators (URLs).
27. The method of Claim 25 wherein the certain
10 locations are table entries.
28. The method of Claim 24 further comprising the steps of:
partitioning a bit map into multiple sections;
and
15 associating each section with a different indicator.
29. The method of Claim 24 wherein the desired control element is a file tab control, comprising a left
piece bitmap, a right piece bitmap, and a center
20 piece bitmap.
30. The method of Claim 29 wherein left and right bitmaps of adjacent right and left control elements are shared.
31. The method of Claim 24 wherein a desired control is
25 a linear control, further comprising:

button control elements spaced at intervals along a line, wherein each button control element is a bit map or combination of bit maps; and a pointer to indicate a current value along the line.

- 5
32. The method of Claim 24 wherein the SGML-derived document is in HTML.
33. The method of Claim 24 wherein the SGML-derived document is in XML.
- 10 34. The method of Claim 24 wherein the server is stateless with respect to the GUI control.
35. The method of Claim 24 wherein at least one bit map is used by a plurality of similar GUI controls.
- 15 36. A method of entering clinical trial data from a client, whereby the data is maintained on a server, the method comprising:
- generating, at the server, a data entry form to be displayed at the client, the data entry form being generated dynamically in a SGML-derived language, control elements within the form comprising bitmaps which selectively and in combination construct the control elements, individual bitmaps being used within the plural control elements.
- 20
- 25 37. The method of Claim 36, further comprising:

displaying, at a client, selected clinical trial data based on any or all of a user, a patient, a protocol version within a clinical trial, and data previously entered.

5 38. The method of Claim 36 further comprising:

creating a protocol database which is specific to an application;

creating a data database which is specific to a subject processed by the application;

10 generating the form based on the protocol database and a context received from the client;

populating the form with application data from the data database; and

15 publishing the populated form to the client browser.

39. A method of discouraging inadvertent use of a computer application, comprising:

requiring an authentication procedure for each user; and

20 displaying a picture of an authenticated user.

40. A system for constructing a graphical user interface (GUI) application, comprising:

25 a protocol database which is specific to an application for which data is input and displayed through a client browser;

a data database which is specific to a subject processed by the application;

a template generator which generates a template based on the protocol database and a context received from the client;

5 a template populator which populates the template with application data from the data database; and

a content server which publishes the populated template to the client browser as an SGML-derived form for input and display of data for the application.

10

41. The system of Claim 40 further comprising:

a plurality of frames, some of the frames being control frames comprising one or more control elements, other frames being intermediate frames to be shared by the control frames, appearance of the intermediate frames depending on visual states of the control frames.

15

42. A computer system for entering clinical trial data, comprising:

20 a form displayed on a computer screen, the form having at least one question to which a user must respond to provide clinical data; and

links between text of each question and detailed information related to the question, the detailed information existing in at least one on-line document, such that if the user clicks on text of the question, displaying detailed information corresponding to the question is displayed.

25

43. A system for implementing a graphical user interface (GUI) control element within a client browser, comprising:

5 construction means for constructing the GUI control element in plural states from a plurality of bitmaps;

10 placement means for placing the bitmaps within a Standard Generalized Markup Language (SGML)-derived document such that upon receipt of the document at the browser, the browser will display a desired GUI control.

- 15 44. The system of Claim 43 wherein placement means further comprises a table means for placing indicator means to the bit maps in certain locations within the document, such that the browser will correctly display the control element.

45. A system for constructing a graphical user interface (GUI) application, comprising:

20 protocol database means specific to an application for which data is input and displayed through a client browser, and data database means which is specific to a subject processed by the application;

25 generation means for generating a template based on the protocol database means and a context received from the client;

template populating means for populating the template with application data from the data database means; and

publishing means for publishing the populated template via a content server to the client browser as an SGML-derived form for input and display of data for the application.

- 5 46. A system for implementing a graphical user interface (GUI) control element within a client browser, comprising:
- 10 a plurality of bitmaps which selectively and in combination may be constructed to present the GUI control element in plural states;
- 15 a Standard Generalized Markup Language (SGML)-derived document in which placement of the bitmaps is specified such that upon receipt of the document at the browser, the browser will display a desired GUI control.
- 20 47. The system of Claim 46 wherein placement of the bitmaps is specified by placing indicators to the bit maps in certain locations within the document, such that the browser will correctly display the control element.
48. The system of Claim 47 wherein the indicators are uniform resource locators (URLs).
49. The system of Claim 47 wherein the certain locations are table entries.
- 25 50. The system of Claim 46 wherein a bit map comprises multiple sections, each section being associated with a different indicator.

51. The system of Claim 46 wherein the SGML-derived document is in HTML.
52. The system of Claim 46 wherein the server is stateless with respect to the GUI control.
- 5 53. The system of Claim 46 wherein at least one bit map is used by a plurality of similar GUI controls.
54. A system for entering clinical trial data from a client, where the data is maintained on a server, the system comprising:
- 10 a data entry form generator to dynamically generate a form in a SGML-derived language, the form to be displayed at the client, control elements within the form comprising bitmaps which selectively and in combination construct the
- 15 control elements, said bitmaps being multiply used within the control elements, the form being generated according to any or all of a user, a patient, a protocol version within a clinical trial and data previously entered.
- 20
55. The system of Claim 54, wherein selected clinical trial data are displayed at a client, the selection being based on any or all of a user, a patient, a protocol version within a clinical trial, and data
- 25 previously entered.
56. A computer system which discourages inadvertent use of a computer application, comprising:
- an authentication procedure for each user; and

a picture display, within the application, of an authenticated user.




FIG. 1




FIG. 2




FIG. 3

3/17

250

251B

263

Week-4 Week-2 Week-1 Week2 Week3 Week4 Week5 Week6 Week7 Week8

IF DEM HH SS PE VS/BP ECG/CXR LAB CM 265

Demographics

■ Ready for SDV Patient: JPK PatientNo:OI-001

Demographics

1. Gender ☐ Male ☒ Female

2. Date of Birth Feb 19 1964

3. Race/Ethnic Origin ☒ Black ☐ Other (specify)

4. Height: 66 ☐ In ☐ Ocm

5. Weight: 145 ☐ lb ☐ Okg

6. Frame: Medium

Calculated weight variance from avg. % Above / Below

Application Data 255

Smoking History

7. Has patient ever smoked? ☐ Yes ☒ No ☐ Not Done
You indicated that the patient smokes cigarettes in item 9. Please check that no is the correct answer to "Has the patient ever smoked?"

8. If the patient has ever smoked, has the patient quit smoking? ☐ Yes ☒ No ☐ Not Done

9. If the patient currently smokes, the patient smokes: ☒ Cigarettes ☐ Cigars ☐ Pipe ☐ Not Done

10. If the patient has ever smoked cigarettes, enter the average number of packs smoked per day: 1 ☐ OUnknown ☐ ONot Done

Submit Cancel

251A

269

271

257

259

261

271

Form Layout 253

FIG. 4A

267

251C

JPH/OI: Wk-4 Dem
JPH/OI: Wk-4 ECG
JPH/OI: T & E Sched
Site OI GRBs

Home Help Logout
Enrollment
Visits
Queries
Status
Documents


Jennifer Smith, RN
Clinical Research
Coordinator

FIG. 4A

Form Layout 253

4/17

Application Layout



Jennifer Smith, RN
Clinical Research
Coordinator

Home Help Logout

Enrollment

Visits

Queries

Status

Documents

Week-4 Week-2 Week1 Week2 Week3 Week4 Week5 Week6 Week7 Week8

IF DEM HH SS PE VS/BP ECG/CXR LAB CM

Demographics

■ Ready for SDV Patient: JPK Patient No: OI-001

Demographics		557A	557B	557C
1. Gender	<input type="radio"/> Male <input checked="" type="radio"/> Female			556
2. Date of Birth	Feb 19 1964			554
3. Race/Ethnic Origin	<input checked="" type="radio"/> Black <input type="radio"/> Other (specify)			553
4. Height	66 in			555
5. Weight	145 lb			
6. Frame	Medium			
Calculated weight variance from avg.		Application Data		

Smoking History

7. Has patient ever smoked? ☐ Yes ☒ No ☐ Not Done
You indicated that the patient smokes cigarettes in item 9. Please check that no is the correct answer to "Has the patient ever smoked?"

8. If the patient has ever smoked, has the patient quit smoking? ☐ Yes ☒ No ☐ Not Done

9. If the patient currently smokes, the patient smokes: ☒ Cigarettes ☐ Cigars ☐ Pipe ☐ Not Done

10. If the patient has ever smoked cigarettes, enter the average number of packs smoked per day: ☐ Unknown ☐ Not Done

JPH/OI: Wk-4 Dem

JPH/OI: Wk-4 ECG

JPH/OI: T&E Schec

Site OI GRBs

Form Layout 253

Submit Cancel

FIG. 4B




FIG. 4C




FIG. 4D

7/17

275
251B

Week-4 Week-2 Week1 Week2 Week3 Week4 Week5 Week6 Week7 Week8	
IF DEM HH SS PE VS/BP ECG/CXR LAB CM	
■ Ready for SDV Patient: JPK Patient No: 01-001	
Demographics	
1. Gender	Female
2. Date of Birth	Feb 19, 1954
3. Race/Ethnic Origin	Black
4. Height:	66 in
5. Weight:	145 lb.
6. Frame:	Medium
Calculated weight variance from avg. — % Above / Below	
Smoking History	
7. Has patient ever smoked ?	No
<i>You indicated that the patient smokes cigarettes in item 9. Please check that no is the correct answer to "Has the patient ever smoked?"</i>	
8. If the patient has ever smoked, has the patient quit smoking ?	No
9. If the patient currently smokes, the patient smokes:	Cigarettes
10. If the patient has ever smoked cigarettes, enter the average number of packs smoked per day:	1

John F. Raymond
Laboratory Assistant

Home Help Logout

Enrollment

Visits

Queries

Status

Documents

Signatures

Monitor

JPH/OI: Wk-4 Dem

JPH/OI: Wk-4 ECG

JPH/OI: T&E Sched

Site OI GRBs

Next Reverse Exit

251C

FIG. 5

291

PHASE FORWARD

InForm™

Please enter your name and password

Account name

jsmith

Password

Log in



293
295

297

FIG. 6

[illegible]

FIG. 7



10/17




FIG. 10A




FIG. 10B









FIG. 10C





PROTOCOL VERSION 1

620

621

623

625

FIG. 12B

PROTOCOL VERSION 2

1		Date of Assessment:	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
2		Blood Pressure Reading 1:	<input type="text"/>	/	<input type="text"/>	Mm Hg	
3		Blood Pressure Reading 2:	<input type="text"/>	/	<input type="text"/>	Mm Hg	
4		Blood Pressure Reading 3:	<input type="text"/>	/	<input type="text"/>	Mm Hg	

FIG. 12C

15/17

Help Link
801

Week-4 Week-2 Week1 Week2 Week3 Week4 Week5 Week6 Week7 Week8

IF DEM HH SS PE VS/BP ECG/CXR LAB CM

Demographics Ready for SDV Patient: JPK Patient No: OI-001

Demographics

1. Gender ☐ Male ☒ Female

2. Date of Birth Feb 19 1964

3. Race/Ethnic Origin ☒ Black ☐ Other (specify)

4. Height: 66 ☒ in ☐ cm

5. Weight: 145 ☒ lb ☐ kg

6. Frame: Medium

Calculated weight variance from avg. ___% Above/Below

Smoking History

7. Has patient ever smoked? ☐ Yes ☒ No ☐ Not Done
You indicated that the patient smokes cigarettes in item 9. Please check that no is the correct answer to "Has the patient ever smoked?"

8. If the patient has ever smoked, has the patient quit smoking? ☐ Yes ☒ No ☐ Not Done

9. If the patient currently smokes, the patient smokes: ☒ Cigarettes ☐ Cigars ☐ Pipe ☐ Not Done

10. If the patient has ever smoked cigarettes, enter the average number of packs smoked per day: ☒ 1 ☐ Unknown ☐ Not Done

Submit Cancel

FIG. 13A

Context Sensitive
Help 804

Help Window
803

Week-4 Week-2 Week1 Week2 Week3 Week4 Week5 Week6 Week7 Week8

IF DEM HH SS PE VS/BP ECG/CXR LAB CM

Demographics Ready for SDV Patient: JPK Patient No: OI-001

Demographics

Item 4. Height

- Height must be measured
- Measure height with shoes off
- Report height in either inches or centimeters. (The entry will be converted to the desired units for report purposes.)

Item 5 Weight

- How often will the weight be measured
- Check the number to be the number that should be entered

Item 6 Frame

- How the measurement here will be used
- Use the number that is closest to the actual weight

Smoking History

9. If the patient currently smokes, the patient smokes: ☒ Cigarettes ☐ Cigars ☐ Pipe ☐ Not Done

10. If the patient has ever smoked cigarettes, enter the average number of packs smoked per day: ☒ 1 ☐ Unknown ☐ Not Done

Protocols Study Guide Help Investigator Brochure Close

Submit Cancel

FIG. 13B

16/17

Help Button
807

251A

Week-4 Week-2 Week-1 Week-2 Week-3 Week-4 Week-5 Week-6 Week-7 Week-8

IF DEM HH SS PE VS/BP ECG/CXR LAB CM

Demographics ■ Ready for SDV Patient: JPK Patient No: 01-001

Demographics

1. Gender ☐ Male ☒ Female

2. Date of Birth Feb 19 1964

3. Race/Ethnic Origin ☒ Black ☐ Other (specify)

4. Height: 66 in ☒ lb ☐ kg

5. Weight: 145

6. Frame: Medium

Calculated weight variance from avg. % Above/Below

Smoking History

7. Has patient ever smoked? ☐ Yes ☒ No ☐ Not Done
You indicated that the patient smokes cigarettes in item 9. Please check that no is the correct answer to "Has the patient ever smoked?"

8. If the patient has ever smoked, has the patient quit smoking? ☐ Yes ☒ No ☐ Not Done

9. If the patient currently smokes, the patient smokes: ☒ Cigarettes ☐ Cigars ☐ Pipe ☐ Not Done

10. If the patient has ever smoked cigarettes, enter the average number of packs smoked per day: ☐ 1 ☐ Unknown ☐ Not Done

Submit Cancel

FIG. 13C

810

811

Help Window
809

Week-4 Week-2 Week-1 Week-2 Week-3 Week-4 Week-5 Week-6 Week-7 Week-8

IF DEM HH SS PE VS/BP ECG/CXR LAB CM

Demographics ■ Ready for SDV Patient: JPK Patient No: 01-001

Demographics

Phase Forward Help-Microsoft Internet Explorer

Contents Index

Welcome to Clinical Trial Information Environment

Basics

Introducing CTE

Navigating

Managing patient data

Monitoring

Protocols Study Guide Help Investigator Brochure Close

10. If the patient has ever smoked cigarettes, enter the average number of packs smoked per day: ☐ 1 ☐ Unknown ☐ Not Done

Submit Cancel

805

FIG. 13D

811

17/17




FIG. 13E

812




FIG. 13F



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)


(51) International Patent Classification ⁶ : G06F 19/00, 9/44		A3	(11) International Publication Number: WO 99/63473
			(43) International Publication Date: 9 December 1999 (09.12.99)
(21) International Application Number: PCT/US99/12406		(81) Designated States: DE, GB, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 3 June 1999 (03.06.99)			
(30) Priority Data: 09/092,441 5 June 1998 (05.06.98) US		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(71) Applicant: PHASE FORWARD INC. [US/US]; 51 Winchester Street, Newton, MA 02461 (US).		(88) Date of publication of the international search report: 27 January 2000 (27.01.00)	
(72) Inventors: BLEICHER, Paul, A.; 174 Mt. Vernon Street, Newton, MA 02165 (US). STAMOS, Nicholas; 22 Jeannette Avenue, Belmont, MA 02478 (US). KLOFFT, Jeffrey, P.; 33 Hamilton Circle, Marlborough, MA 01752 (US). DALE, Richard, M.; 117 Russell Street, Newton, MA 02165 (US).			
(74) Agents: SMITH, James, M. et al.; Hamilton, Brook, Smith & Reynolds, P.C., Two Militia Drive, Lexington, MA 02421 (US).			

(54) Title: CLINICAL TRIAL DATA MANAGEMENT SYSTEM AND METHOD

(57) Abstract

A system and method for managing clinical trial data includes dynamically generating, at a server, a data entry form to be displayed at a client. The data entry form is generated dynamically in a SGML-derived language. Control elements within the form comprise images which are used to construct the control elements and larger controls. The form is generated from a protocol database and a context received from the client, is populated from the data database, and is published to the client. Templates based on the protocol database comprise several frames including intermediate frames for displaying frame borders which are non-horizontal

and non-vertical. If the trial protocol changes during a trial, the generated form is based on the protocol version active at the time data was entered into the form. Inadvertent use of the application is discouraged requiring an authentication procedure and displaying a picture of the authenticated user. Furthermore, help is provided by creating a link between the text of each question and information about the question. The source of help may be any or all of a protocol document, an investigative brochure, and a study guide. In addition, a user, upon logging in, is presented with a dashboard screen which provides information or links to information such as trial-related news, alerts, statistical information, progress reports and a list of work to be completed.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 99/12406

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 G06F19/00 G06F9/44

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 G06F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>KIUCHI T ET AL: "Automated generation of a World Wide Web-based data entry and check program for medical applications" COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE, FEB. 1997, ELSEVIER, NETHERLANDS, vol. 52, no. 2, - February 1997 (1997-02) pages 129-138, XP002123139 ISSN: 0169-2607 the whole document</p> <p style="text-align: center;">— — — — — -/-</p>	1-56



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

18 November 1999

Date of mailing of the international search report

03/12/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5618 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Fonderson, A

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/12406

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>KELLY M A ET AL: "The Internet and randomised controlled trials" INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS, IR, ELSEVIER SCIENTIFIC PUBLISHERS, SHANNON, vol. 47, no. 1-2, - 1997 page 91-99 XP004107516 ISSN: 1386-5056 the whole document</p>	1-56
A	<p>"MULTI-STATE BUTTON MANIPULATION USING A SINGLE GRAPHIC" IBM TECHNICAL DISCLOSURE BULLETIN, US, IBM CORP. NEW YORK, vol. 38, no. 4, page 585-587 XP000516262 ISSN: 0018-8689 the whole document</p>	5, 24, 25, 28-31, 35, 36, 43, 44, 46, 47, 50, 53, 54
A	<p>ANONYMOUS: "Efficient 3D Buttons in Dynamic Hyper Text Markup Language Pages" IBM TECHNICAL DISCLOSURE BULLETIN, vol. 41, no. 1, pages 695-698, XP002123140 New York, US the whole document</p>	5, 24, 25, 28-31, 35, 36, 43, 44, 46, 47, 50, 53, 54
A	<p>GIRGENSOHN A ET AL: "Seamless integration of interactive forms into the Web" COMPUTER NETWORKS AND ISDN SYSTEMS, NL, NORTH HOLLAND PUBLISHING. AMSTERDAM, vol. 29, no. 8-13, page 1531-1542 XP004095347 ISSN: 0169-7552 the whole document</p>	7-17, 42
A	<p>NETSCAPE COMMUNICATIONS CORP.: "NetHelp" NETHELP RELEASE 1.0 SDK DOCUMENTATION, 'Online! - August 1996 (1996-08) pages 1-14, XP002071214 USA Retrieved from the Internet: <URL:http://home.nestcape.com/eng/help/sdk1/sdksite.htm> 'retrieved on 1998-07-10! the whole document</p>	7-17, 42